Akums Drugs and Pharmaceuticals Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report details the company's adherence to the National Guidelines on Responsible Business Conduct (NGRBC) principles, covering environmental, social, and governance aspects of its operations. The disclosures have been assured by BDO India Services Private Limited, with reasonable assurance provided for core indicators and limited assurance for essential and leadership indicators.

Environmental Performance

The company reported a total energy consumption of 10,96,245.52 GJ for FY 2025-26, compared to 10,68,818.03 GJ in the previous year. Energy intensity per ₹ crore of turnover improved to 251.49 GJ from 259.54 GJ. Renewable energy sources contributed 3,36,446.52 GJ to the total consumption. Total Scope 1 and Scope 2 greenhouse gas emissions were 1,38,181.40 metric tonnes of CO2 equivalent, with an emission intensity of 31.65 metric tonnes per ₹ crore of revenue.

Water withdrawal totalled 11,34,998.46 kilolitres, primarily from groundwater sources. Water discharge was reported at 1,04,240.89 kilolitres. The company operates Zero Liquid Discharge (ZLD) facilities at three manufacturing sites. Waste generation totalled 9,204.67 metric tonnes, with 6,591.61 metric tonnes recovered through recycling, reusing, or other recovery operations.

Social and Governance Metrics

The company employed 6,455 permanent employees and 11,555 workers as of the end of FY 2025-26. The workforce included 31 differently abled employees and 18 differently abled workers. The Board of Directors comprised 8 members, with female representation at 12.50%. The company reported 4 sexual harassment complaints during the year, all of which were resolved.

Financial and Regulatory Disclosures

The report disclosed that the company paid penalties totaling ₹8,34,999 during the year for various regulatory non-compliances, including issues related to misbranding and stock exchange regulations. The company’s turnover stood at ₹1,348.74 crore, and its net worth was ₹2,305.25 crore. Akums Drugs and Pharmaceuticals Limited continues to focus on integrating ESG considerations into its business strategy, with initiatives aimed at improving energy efficiency, water stewardship, and waste management.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE09XN01023/85efcf7226914b05.pdf

Akums Drugs and Pharmaceuticals Limited has scheduled two investor and analyst meets for June 15, 2026, to engage with the investment community. The company will participate in the India Conclave Conference and the Small-Cap Investor Conference, both commencing at 09:00 A.M. (IST). These meetings provide a platform for the company to present its business outlook and operational performance directly to market participants.

The disclosure was made to the National Stock Exchange of India Ltd. and BSE Limited pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Akums Drugs & Pharma clarified that no unpublished price sensitive information will be shared during these interactions.

The meetings are categorized as group meets and will be held in two different locations. The schedule details are as follows:

The company noted that the schedule may be subject to change due to exigencies on the part of the host or the company. A copy of the disclosure has been updated on the official website of Akums Drugs and Pharmaceuticals Limited. Dharamvir Malik, Company Secretary & Compliance Officer, authorized the filing on June 10, 2026.